The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 27, 2014
Filed:
Jun. 27, 2012
Applicant:
Tihamer Orban, Brookline, MA (US);
Inventor:
Tihamer Orban, Brookline, MA (US);
Assignee:
Orban Biotech LLC, Brookline, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/28 (2006.01); A61K 39/395 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); C07K 14/62 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
A61K 38/28 (2013.01); A61K 38/1774 (2013.01); A61K 39/0008 (2013.01); A61K 2039/55566 (2013.01); C07K 14/62 (2013.01); C07K 14/4713 (2013.01); C07K 14/70521 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01);
Abstract
A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.